BMY - Bristol-Myers Squibb Company
| Previous Close | 62.25 |
| Open | 61.99 |
| Bid | 0.00 x 1000 |
| Ask | 61.99 x 27000 |
| Day's Range | 61.28 - 62.29 |
| 52 Week Range | 49.96 - 70.05 |
| Volume | 3,938,278 |
| Avg. Volume | 5,619,090 |
| Market Cap | 100.507B |
| Beta | 1.11 |
| PE Ratio (TTM) | 273.73 |
| EPS (TTM) | 0.22 |
| Earnings Date | Oct 25, 2018 |
| Forward Dividend & Yield | 1.60 (2.57%) |
| Ex-Dividend Date | 2018-10-04 |
| 1y Target Est | 59.65 |
- Zacks•14 hours ago
AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU
The CHMP gives positive opinion for combination use of AbbVie's (ABBV) Venclexta and Roche's Rituxan for relapsed/refractory CLL in patients who have received at least one prior therapy.
- Zacks•15 hours ago
AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk
AstraZeneca's (AZN) Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in a cardiovascular outcomes study.
- Market Realist•3 days ago
How Does Sage Therapeutics’ Product Portfolio Look in September?
Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.
Markit•4 days agoSee what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co NYSE:BMY
- American City Business Journals•4 days ago
Flexible labs, co-working space: Big Pharma is rethinking real estate
At an industry event Thursday, representatives from both Merck & Co. and Bristol-Myers Squibb stressed the importance of flexibility in real-estate assets.
- Zacks•5 days ago
Bristol-Myers' MM Drug Empliciti Application Validated by EMA
Bristol-Myers' (BMY) application for multiple myeloma drug, Empliciti gets validated in Europe.
- Zacks•6 days ago
Is Bristol-Myers Squibb (BMY) a Great Dividend Play?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
- Zacks•6 days ago
Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff
Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.
- Zacks•7 days ago
Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern
Bayer (BAYRY) focuses on acquisitions and deals in order to boost growth as well as portfolio.
- Zacks•7 days ago
Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.
Markit•7 days agoSee what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co NYSE:BMY
- Business Wire•7 days ago
European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma
Bristol-Myers Squibb Company today announced that the European Medicines Agency has validated the Company’s type II variation application for Empliciti in combination with pomalidomide and low-dose dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor , and have demonstrated disease progression ...
- Market Realist•8 days ago
How Is Merck’s Keytruda Positioned in September?
Merck’s (MRK) Keytruda has witnessed ~89% YoY (year-over-year) growth and generated second-quarter revenues of $1.7 billion. In the US market, Keytruda’s second-quarter revenues grew 73.0% to reach $959.0.0 million. In the international markets, Keytruda’s revenues increased ~118.0% YoY to reach $707.0.0 million.
- GuruFocus.com•8 days ago
Bristol-Myers Squibb's New Psoriasis Drug Has Echoes of Humira
Could Bristol-Myers Squibb (BMY) be the one to come out with the next Humira? Probably not, but its new drug candidate for plaque psoriasis BMS-986165 at least has a shot to come within the same ballpark. How did Humira get to be the best-selling drug of all time, and why should Bristol-Myers' new candidate dare at all compare?
- Market Realist•10 days ago
uniQure: Its Promising Research Pipeline
It has a collaboration with Bristol-Myers Squibb (BMY) that’s targeted at cardiovascular disease. AMT-130 has received orphan drug designation in the United States and orphan medicinal product designation from the European Medicines Agency.
Zacks•11 days agoPharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
- Simply Wall St.•12 days ago
Bristol-Myers Squibb Company (NYSE:BMY) Is Trading At A 23.98% Discount
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Bristol-Myers Squibb Company (NYSE:BMY) as an investment opportunity by taking theRead More...
Markit•12 days agoSee what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co NYSE:BMY
- Business Wire•12 days ago
Bristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty cents per share on the $.10 par value Common Stock of the corporation.
- Reuters•13 days ago
Bristol-Myers plaque psoriasis drug shows promise in mid-stage trial
Bristol-Myers Squibb said on Wednesday its experimental drug helped reduce the severity of the most common form of psoriasis in a mid-stage trial. The study tested the drug, BMS-986165, in 267 patients with plaque psoriasis, a chronic condition that causes dry, red skin lesions covered with silvery scales. After 12 weeks, between 67 percent and 75 percent of patients given a 3-milligram dose twice daily, or a higher dose, showed a 75 percent reduction on a scale called PASI that is considered the benchmark of main goals for most psoriasis clinical trials.
Yahoo Finance•13 days agoApple under pressure, Tiffany moves higher, Bristol-Myers Squibb dips
Let’s check out the Yahoo Finance charts of the day.
- InvestorPlace•13 days ago
The Outlook for AstraZeneca Is Positive, But It’s Too Early to Pull the Trigger
AstraZeneca’s (NYSE:AZN) profits look poised to resume growing, as a number of the drug company’s new treatments are expected to be approved by regulators. While ultimately the new drugs should compensate for the lost Crestor sales, it’s too early to say when the positive outlook will be reflected in AZN stock. If these forecasts hold, and AZN stock can trade consistently above $40 per share, AstraZeneca stock could finally rally.
- Zacks•13 days ago
Merck's Antibacterial Drug Succeeds in Label Expansion Study
Merck's (MRK) label expansion study evaluating its antibacterial drug, Zerbaxa for two types of pneumonia infections meets primary endpoints.
- Zacks•13 days ago
Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus
Here we take a look at companies with approved immunotherapy therapies or pipeline candidates for the treatment of widely prevalent NSCLC.
- Zacks•13 days ago
Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug
Bristol-Myers Squibb (BMY) announces encouraging data from a phase II study on plaque psoriasis candidate.
